A Phase 1, Single Site, Open-label, Uncontrolled Study of FF-21101In / FF-21101Y in Patients with Solid Tumors that Relapsed or Metastasized after Standard Therapy
A Phase 1, Single Site, Open-label, Uncontrolled Study of FF-21101In / FF-21101Y in Patients with Solid Tumors that Relapsed or Metastasized after Standard Therapy
A phase II clinical study of F-1614 in patients with pheochromocytoma (including paraganglioma)
100 项与 PDRadiopharma, Inc. 相关的临床结果
0 项与 PDRadiopharma, Inc. 相关的专利(医药)
100 项与 PDRadiopharma, Inc. 相关的药物交易
100 项与 PDRadiopharma, Inc. 相关的转化医学